Sun Pharmaceutical Industries Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharmaceutical Industries Ltd.
Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.
All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.
Sun Pharma and some members of its senior leadership have settled a case pertaining to related party transactions and compliance deviations raised in whistleblower complaints in India.
90%-95% of specialty doctors are back at their clinics in India and pharma field force personnel are again on the move, though patient footfall is yet to fully normalize, the country’s largest drug firm Sun has indicated. While the situation isn’t quite the same in the US, the company reported sales growth in both key geographies in Q3.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aditya Acquisition Company ltd
- Caraco Pharmaceutical Laboratories, Ltd.
- DUSA Pharmaceuticals, Inc.
- InSite Vision, Inc.
- JSC Biosintez
- Ocular Technologies
- Pola Pharma Inc.
- Ranbaxy Laboratories Limited
- Ranbaxy Solus
- Solus Care
- Sun Ophthalmics
- Sun Pharma Global FZE